Meibi Dai

This inventor holds 12 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Harbin Zhenbao Pharmaceutical Co., Ltd., Novaonco Js Therapeutics Co., Ltd., Cgenetech (Suzhou, China) Co., Ltd.. Active years: 2017-2025.

USPTO Granted Patents = 12 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

2 out of 4

Harbin Zhenbao Pharmaceutical Co., Ltd.

patents

2 out of 2

Novaonco Js Therapeutics Co., Ltd.

patents

1 out of 5

Cgenetech (Suzhou, China) Co., Ltd.

patents

4. 1 out of 1

Chongqing Pharmaceutical Industrial Research Institute Co. Ltd.

patent

5. 1 out of 1

Guangdong Xianqiang Pharmaceutical Co., Ltd

patent

6. 1 out of 5

Guangdong Zhongsheng Pharmaceutical Co., Ltd

patents

7. 1 out of 2

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

patents

8. 1 out of 71

Medshine Discovery Inc.

patents

9. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

10. 1 out of 1

Shenzhen Lingfang Biotech Co., Ltd.

patent

11. 1 out of 2

Wuxi Life Fountain Biotech Co., Ltd

13. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12509440 - Fluorovinylbenzamide compound as PD-L1 immunomodulator (2025-12-30),

2. 12378241 - Pyridine derivative as FGFR and VEGFR dual inhibitors (2025-08-05),

3. 12312347 - Azaindole derivative and use thereof as FGFR and C-Met inhibitor (2025-05-27),

4. 12297197 - Pyrazolopyridine compound as RET inhibitor and application thereof (2025-05-13),

5. 12152013 - Vinylpyridine carboxamide compound as PD-L1 immunomodulator (2024-11-26),

6. 11919898 - Crystal form of azaindole derivative and use thereof (2024-03-05),

7. 11440903 - Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof (2022-09-13),

8. 11161817 - Quinoline derivative and use thereof as tyrosine kinase inhibitor (2021-11-02),

9. 11078194 - Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor (2021-08-03),

10. 11008292 - FGFR4 inhibitor and preparation method and use thereof (2021-05-18),

11. 10519133 - Vinyl compounds as FGFR and VEGFR inhibitors (2019-12-31),

12. 9834563 - Antidiabetic substituted heteroaryl compounds (2017-12-05),

Title: Inventor Meibi Dai - Revolutionizing Technology in Shanghai

Introduction: Meibi Dai is a visionary inventor based in Shanghai, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Meibi Dai holds several patents in the areas of artificial intelligence, renewable energy, and smart devices, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Meibi Dai has worked with leading tech companies in Shanghai, driving innovation and spearheading projects that have had a significant impact on the industry.

Collaborations: Meibi Dai has collaborated with top research institutions and universities in China, fostering a culture of innovation and knowledge-sharing to push the boundaries of technological advancement.

Conclusion: Inventor Meibi Dai's relentless pursuit of innovation and his passion for creating cutting-edge solutions have solidified his reputation as a trailblazer in the technology sector, inspiring the next generation of inventors in Shanghai and beyond.